Acessa has developed Acessa ProVu, a laparoscopic-based system that combines radiofrequency (RF) ablation with ultrasound visualization and guidance mapping. Acessa ProVu enables physicians to treat women with symptomatic benign uterine fibroids as an alternative to open surgery.
Hologic notes that uterine fibroids affect between 50% and 60% of women, a percentage that increases to about 70% by age 50. The condition can cause heavy menstrual bleeding, pain, frequent urination, and other symptoms.
Acessa ProVu is designed to detect more fibroids as compared with the use of current imaging modalities, according to Hologic. RF fibroid ablation is supported by clinical data that demonstrates that the treatment results in less blood loss and faster recovery times compared with conventional more invasive treatments.
Hologic believes that Acessa Health will produce about $13 million of revenue in fiscal 2021. The company will be integrated into Hologic's GYN Surgical business.
Copyright © 2020 AuntMinnie.com